GPCR - CIK 0001888886
Structure Therapeutics Inc. trades as GPCR and has a market capitalization of $2.81 B, making it the #1858 largest US-listed company by market value. This page tracks Structure Therapeutics Inc. through 248 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Prospectus supplement | 424B5 | 2026-05-07 |
| Insider trade | 4 | 2026-04-23 |
| New insider ownership | 3 | 2026-04-23 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| Insider trade | 4 | 2026-04-16 |
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity | Structure Therapeutics
Structure Therapeutics Announces Participation in Upcoming Investor Conferences | Structure Therapeutics
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Structure Therapeutics
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions | Structure Therapeutics
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | Structure Therapeutics
The largest companies sharing Structure Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
Structure Therapeutics Inc. (GPCR) has a market capitalization of $2.81 B as of 2026-05-29, ranking #1858 among US-listed companies.
In its latest fiscal year Structure Therapeutics Inc. reported a net loss of $141.20M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.